Adaptive Biotechnologies trims handful of jobs as strategic review nears completion

Adaptive Biotechnologies, a Seattle-based diagnostics maker and drug discovery company, told Endpoints News it recently eliminated about 49 roles as part of its strategic review.

According to a securities filing, the company had 790 full-time workers at the end of 2022, the most recent year for which data are available….
Click here to view original post

Click Here to Publish/Feature Your Company or Product News with Biotech Networks